U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Optical Activity ( + )
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUINIDINE

SMILES

COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1

InChI

InChIKey=LOUPRKONTZGTKE-LHHVKLHASA-N
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Quinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. Like all other class I antiarrhythmic agents, quinidine primarily works by blocking the fast inward sodium current (INa). Quinidine's effect on INa is known as a 'use-dependent block'. This means at higher heart rates, the block increases, while at lower heart rates, the block decreases. The effect of blocking the fast inward sodium current causes the phase 0 depolarization of the cardiac action potential to decrease (decreased Vmax). Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICA), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito. Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6 and can lead to increased blood levels of lidocaine, beta blockers, opioids, and some antidepressants. Quinidine also inhibits the transport protein P-glycoprotein and so can cause some peripherally acting drugs such as loperamide to have central nervous system side effects, such as respiratory depression if the two drugs are coadministered. Quinidine can cause thrombocytopenia, granulomatous hepatitis, myasthenia gravis, and torsades de pointes, so is not used much today. Torsades can occur after the first dose. Quinidine-induced thrombocytopenia (low platelet count) is mediated by the immune system and may lead to thrombocytic purpura. A combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. This drug is marketed as Nuedexta in the United States. Intravenous quinidine is also indicated for the treatment of Plasmodium falciparum malaria. However, quinidine is not considered the first-line therapy for P. falciparum. The recommended treatments for P. falciparum malaria, according to the Toronto Notes 2008, are a combination of either quinine and doxycycline or atovaquone and proguanil (Malarone). The drug is also effective for the treatment of atrial fibrillation in horses.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
TASK-3, a new member of the tandem pore K(+) channel family.
2000 Mar 31
Alteration of drug kinetics in rats following exposure to trichloroethylene.
2001
Pharmacokinetic interactions of antimalarial agents.
2001
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.
2001
CIBIS, MERIT-HF, and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhythmic and antifibrillatory drugs?
2001 Apr
HPTLC method for the estimation of alkaloids of Cinchona officinalis stem bark and its marketed formulations.
2001 Apr
Quinidine and malaria.
2001 Apr 23
Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms.
2001 Apr 27
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis.
2001 Aug
[Pharmacokinetics and drug interactions of antidepressive agents].
2001 Aug
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
2001 Aug
Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.
2001 Feb
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.
2001 Feb
Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells.
2001 Feb
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
From the Centers for Disease Control and Prevention. Availability and use of parenteral quinidine gluconate for severe or complicated malaria.
2001 Feb 14
A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.
2001 Jan
Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers.
2001 Jan
Sympathetic activation enhances QT prolongation by quinidine.
2001 Jan
How do I prolong QT? Let me count the ways.
2001 Jan
Transport of [3H]MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4).
2001 Jan
A novel zidovudine uptake system in microglia.
2001 Jan
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction.
2001 Jan
Salt and cosolvent effects on ionic drug loading into microspheres using an O/W method.
2001 Jan 29
Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems.
2001 Jan 29
Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
2001 Jul
A direct injection capillary electrophoretic technique for miniaturized high-throughput metabolic screening of the CYP 3A4 enzyme using quinidine as a probe.
2001 Jul
In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin.
2001 Jun
Ascorbic acid-induced modulation of venous tone in humans.
2001 Mar
Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole.
2001 Mar
Moxifloxacin: clinical efficacy and safety.
2001 Mar 1
Effect of hydrophilic substances on liberation of quinidine from starch - alginate sphere.
2001 Mar-Apr
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
2001 May
Quinidine as an antiarrhythmic.
2001 May
Interactions between antiarrhythmic drugs and cardiac memory.
2001 May
Coumarin substrates for cytochrome P450 2D6 fluorescence assays.
2001 May 15
Drug block of I(kr): model systems and relevance to human arrhythmias.
2001 Nov
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
2001 Oct
GAT2/BGT-1 as a system responsible for the transport of gamma-aminobutyric acid at the mouse blood-brain barrier.
2001 Oct
In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense.
2001 Oct
In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.
2001 Oct
An amino acid residue whose change by mutation affects drug binding to the HERG channel.
2001 Oct 12
Alkaline phosphatase from rat liver and kidney is differentially modulated.
2001 Sep
Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.
2001 Sep
Purinoreceptors are involved in the control of acute morphine withdrawal.
2001 Sep 21
Patents

Sample Use Guides

In Vivo Use Guide
Tablet (sulfate):100 to 600 mg/dose orally every 4 to 6 hours; begin at 200 mg/dose and titrate to desired effect (maximum daily dose: 3 to 4 g). Extended Release: 324 to 648 mg (gluconate) orally every 8 to 12 hours or 300 to 600 mg (sulfate) orally every 8 to 12 hours. IV: 800 mg of quinidine gluconate diluted to 50 mL and given at a rate not to exceed 1 mL/min.
Route of Administration: Oral; intramuscular;
In Vitro Use Guide
Rat brain pericytes were plated onto the backside of 12-well Transwell filters (pore size: 0.4 μm; 1.5 × 104 cells/filter). The next day, endothelial cells were plated onto the upper surface of the filters. After reaching confluency, the endothelial monolayer was supplied with 550 nM hydrocortisone, 250 μM CPT-cAMP, and 17.5 μM RO-201724 and placed into dishes containing glial cultures for 24 h. Transwell filters containing endothelial cells and pericytes were removed from the plates containing the glial culture. Filters were washed with Ringer-HEPES solution (pH 7.4). Quinidine or digoxin was applied at final concentrations of 0.1 μM and 10 μM, respectively. Radiolabeled quinidine and digoxin as tracers were also added to the radioactive concentration of 1 μCi/mL. The inhibitors were added together with the test compound at final concentrations of 1 μM (LY- 335979 and PSC-833) or 100 μM (quinidine). Samples were taken from the basolateral or apical side, respectively, at 15, 30, and 60 min, and radioactivity was measured using a liquid scintillation counter
Substance Class Chemical
Created
by admin
on Mon Oct 21 22:34:48 UTC 2019
Edited
by admin
on Mon Oct 21 22:34:48 UTC 2019
Record UNII
ITX08688JL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUINIDINE
HSDB   MART.   MI   VANDF   WHO-DD  
Common Name English
(+)-QUINIDINE
Common Name English
(9S)-6'-METHOXYCINCHONAN-9-OL
Systematic Name English
QUINIDINE [MART.]
Common Name English
QUINIDINE [WHO-DD]
Common Name English
.BETA.-QUINIDINE
Common Name English
CONQUININE
Common Name English
CINCHONAN-9-OL, 6'-METHOXY-, (9S)-
Common Name English
QUININE HYDROCHLORIDE IMPURITY A [EP]
Common Name English
QUININE SULFATE IMPURITY A [EP]
Common Name English
(8R,9S)-QUINIDINE
Common Name English
QUINIDINE [VANDF]
Common Name English
(S)-((2S,4S,5R)-5-ETHENYL-1-AZABICYCLO(2.2.2)OCT-2-YL)(6-METHOXYQUINOLIN-4-YL)METHANOL
Systematic Name English
QUININE BISULFATE IMPURITY A [WHO-IP]
Common Name English
QUININE BISULFATE HEPTAHYDRATE IMPURITY A [WHO-IP]
Common Name English
PITAYINE
Common Name English
QUININE SULFATE IMPURITY A [WHO-IP]
Common Name English
QUINIDINE [HSDB]
Common Name English
QUINIDINE [MI]
Common Name English
KINIDIN
Common Name English
Classification Tree Code System Code
WHO-VATC QC01BA01
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
WHO-ATC C01BA01
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
WHO-ATC C01BA71
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
NDF-RT N0000175426
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
WHO-VATC QC01BA51
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
NDF-RT N0000182135
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
LIVERTOX 825
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
WHO-VATC QC01BA71
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
WHO-ATC C01BA51
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
Code System Code Type Description
DRUG BANK
DB00908
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
RXCUI
9068
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY RxNorm
NDF-RT
N0000182137
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
LactMed
56-54-2
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
EVMPD
SUB04166MIG
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
MESH
D011802
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
IUPHAR
2342
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
PUBCHEM
441074
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
WIKIPEDIA
QUINIDINE
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
MERCK INDEX
M9446
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY Merck Index
HSDB
56-54-2
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
EPA CompTox
56-54-2
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
ChEMBL
CHEMBL1294
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
ECHA (EC/EINECS)
200-279-0
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
NCI_THESAURUS
C793
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
CAS
56-54-2
Created by admin on Mon Oct 21 22:34:48 UTC 2019 , Edited by admin on Mon Oct 21 22:34:48 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
POTENT
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
BINDER->LIGAND
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE LESS ACTIVE -> PARENT
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
METABOLITE LESS ACTIVE -> PARENT
quinidine is metabolized by CYP3A4 (In vitro)
METABOLITE LESS ACTIVE -> PARENT
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
PARENT -> IMPURITY
Not Specified
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Not Specified
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC Heart Failure
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC